Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jabuticaba leaf intestinal digested fraction is a bioactive extract derived from the leaves of *Myrciaria cauliflora* that has undergone simulated gastrointestinal digestion. This specific fraction is characterized by a distinct phenolic profile, notably containing 3,4-dihydroxybenzoic acid and ferulic acid, which are released or formed during the digestion process. Research indicates that this fraction possesses significant antiproliferative and cytotoxic properties against hepatocellular carcinoma (HepG2) cells. Its mechanism of action involves the induction of both apoptotic and necrotic cell death, inhibition of cell migration, and potent antioxidant activity through the reduction of reactive oxygen species (ROS) generation. It is being bioprospected for potential applications as a nutraceutical or functional food component in the context of cancer prevention and management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jabuticaba leaf intestinal digested fraction.